



SEQENS

PRESS RELEASE | ECULLY, FRANCE - May 19, 2021

Seqens is proud to announce the official partnership between Alganelle and Sederma for the development of a future cosmetic ingredient.

Alganelle (www.alganelle.com) is an innovative biotechnology company with a disruptive technology at the forefront of microalgae synthetic biology, providing a safer, high quality raw material obtained from sustainable processes that respect the environment and biodiversity. The company is led by its inspirational CEO, Dr Ghislaine Tissot-Lécuelle.

Supported financially and technically by Seqens since 2016, Alganelle has just reached an important milestone in its development with the announcement of a strong partnership with Sederma, one of the world leaders in bioactive ingredients for the cosmetics industry.

"This partnership marks a key step in the commercial development of Alganelle and I would like to congratulate the teams for the work they have accomplished. Seqens is confident that Alganelle will be able to impose its technology and unique know-how on other industrial demonstrators in the near future." says Pierre Luzeau, President of SEQENS.

About SEQENS:

Seqens is an integrated player in the development and production of active ingredients, pharmaceutical intermediates and specialty ingredients. With a turnover of more than 1 billion euros, a presence in Europe, North America and Asia, 24 production sites, 7 R&D centers and 3,200 employees, Seqens is one of the European leaders in the sector.

As an integrated player across the value chain - from raw materials to active ingredients and from research and development to industrialization - SEQENS offers a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients, develops and industrializes the most demanding molecules under contract, and relies on its ability to innovate, develop and implement the best available technologies.

Driven by a culture of excellence and a strong entrepreneurial spirit, our 3,200 employees are committed to providing our customers with the highest level of service and quality while acting ethically in accordance with our corporate social responsibility program.

press@seqens.com / www.seqens.com / LinkedIn : SEQENS / Twitter : seqens_group

www.seqens.com

SEQENS SAS, - 21 chemin de la Sauvegarde, 21 Ecully Parc - CS 33167 - 69134 ECULLY Cedex - Share capital 226 890 746.63 euros - 444 465 736 00049 RCS Lyon - Tel : +33 (0)4 26 99 18 00 - Fax : +33 (0)4 26 99 18 38